Objective: The PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA) study is a randomized, placebo-controlled, double-blind trial to determine whether angiotensin receptor blockers (ARB), or beta-blockers or their combination may prevent the development of left ventricular (LV) dysfunction in patients on standard adjuvant treatment for early breast cancer. Methods: Following surgical resection, 120 breast cancer patients scheduled for adjuvant epirubicin-containing chemotherapy and, if indicated, trastuzumab, will be included. They will be randomized to an ARB (candesartan), a beta-blocker (metoprolol) and matching placebos in a 2 × 2 factorial design. The primary objective of the PRADA study is to assess whether prophylactic ARB and/or beta-blockers may prevent a reduction in LV ejection fraction (EF) after adjuvant treatment of early breast cancer, as evaluated by serial cardiovascular magnetic resonance (CMR) performed at randomization, after the first chemotherapy cycle and on its completion, and for subgroups, on completion of radiotherapy or trastuzumab. Secondary outcome measures include echocardiographic indices of LV diastolic dysfunction, structural myocardial alterations assessed by CMR and changes in cardiac biomarkers. Conclusion: PRADA may provide new information on the prophylactic effect of ARB and beta-blockers in patients with early breast cancer regarding the risk of developing cardiac dysfunction from adjuvant cancer treatment.

Keywords:
Echocardiography, Breast cancer, Cardiotoxicity, Cardiovascular magnetic resonance
1.
Ferlay J, Héry C, Autier P, Sankaranarayanan R: Global burden of breast cancer; in Li C (ed): Breast Cancer Epidemiology. New York, Springer, 2010, pp 1–19.
2.
Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR: Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435–1441.
3.
Bird BR, Swain SM: Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008;14:14–24.
4.
Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR: Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 2012;118(8 suppl):2270–2276.
5.
Menna P, Gonzalez Paz O, Chello M, Covino E, Salvatorelli E, Minotti G: Anthracycline cardiotoxicity. Expert Opin Drug Saf 2012;11:21–36.
6.
Roca-Alonso L, Pellegrino L, Castellano L, Stebbing J: Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms? Cardiology 2012;122:253–259.
7.
Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van den Berg MP, et al: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001;19:2746–2753.
8.
Maxwell CB, Jenkins AT: Drug-induced heart failure. American J Health Syst Pharm 2011;68:1791–1804.
9.
Butany J, Ahn E, Luk A: Drug-related cardiac pathology. J Clin Pathol 2009;62:1074–1084.
10.
Chien KR: Herceptin and the heart – a molecular modifier of cardiac failure. New Engl J Med 2006;354:789–790.
11.
Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459–465.
12.
Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, et al: Blockade of the ERBB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 2009;284:2080–2087.
13.
Force T, Krause DS, Van Etten RA: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332–344.
14.
Darby SC, McGale P, Taylor CW, Peto R: Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005;6:557–565.
15.
Little MP, Tawn EJ, Tzoulaki I, Wakeford R, Hildebrandt G, Paris F, et al: Review and meta-analysis of epidemiological associations between low/moderate doses of ionizing radiation and circulatory disease risks, and their possible mechanisms. Radiat Environ Biophys 2010;49:139–153.
16.
Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR: Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004;141:693–704.
17.
Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al: Prevention of heart failure. Circulation 2008;117:2544–2565.
18.
Minotti G, Salvatorelli E, Menna P: Pharmacological foundations of cardio-oncology. J Pharmacol Exp Ther 2010;334:2–8.
19.
Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–2481.
20.
Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al: Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213–220.
21.
Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258–2262.
22.
Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, et al: Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005;104:2492–2498.
23.
Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, et al: Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 2010;160:487 e1–e7.
24.
Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ: Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000;2:271–278.
25.
Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al: Cardiovascular magnetic resonance in myocarditis: A JACC white paper. J Am Coll Cardiol 2009;53:1475–1487.
26.
Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, et al: Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging – a pilot study. Am Heart J 2001;141:1007–1013.
27.
Lightfoot JC, D’Agostino RB Jr, Hamilton CA, Jordan J, Torti FM, Kock ND, et al: Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging 2010;3:550–558.
28.
Senior R, Soman P, Khattar RS, Lahiri A: Improved endocardial visualization with second harmonic imaging compared with fundamental two-dimensional echocardiographic imaging. Am Heart J 1999;138(1 Pt 1):163–168.
29.
Price DJ, Wallbridge DR, Stewart MJ: Tissue Doppler imaging: current and potential clinical applications. Heart 2000;84(suppl 2):II11–II18.
30.
Cho GY, Chan J, Leano R, Strudwick M, Marwick TH: Comparison of two-dimensional speckle and tissue velocity based strain and validation with harmonic phase magnetic resonance imaging. Am J Cardiol 2006;97:1661–1666.
31.
Monaghan MJ: Role of real time 3D echocardiography in evaluating the left ventricle. Heart 2006;92:131–136.
32.
Messroghli DR, Greiser A, Frohlich M, Dietz R, Schulz-Menger J: Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. JMRI 2007;26:1081–1086.
33.
Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517–522.
34.
Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749–2754.
35.
Pituskin E, Haykowsky M, Mackey JR, Thompson RB, Ezekowitz J, Koshman S, et al: Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101–Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 2011;11:318.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.